RetiSpec Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
31
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
22
RetiSpec General Information
Description
Developer of an Artificial Intelligence-driven retinal imaging technology intended for early Alzheimer's detection. The company's technology utilizes a simple eye exam to identify neurodegenerative disease markers, enabling healthcare providers to offer accessible, affordable, and scalable early diagnosis.
Contact Information
Website
www.retispec.comCorporate Office
- 170 Bedford Road
- Unit 200
- Toronto, Ontario M5R 2K9
- Canada
Corporate Office
- 170 Bedford Road
- Unit 200
- Toronto, Ontario M5R 2K9
- Canada
RetiSpec Timeline
RetiSpec Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Accelerator/Incubator | 04-Sep-2024 | Completed | Generating Revenue | |||
| 11. Later Stage VC (Series A) | 26-Jul-2024 | Completed | Generating Revenue | |||
| 10. Accelerator/Incubator | 01-Dec-2023 | Completed | Generating Revenue | |||
| 9. Accelerator/Incubator | 13-Apr-2023 | Completed | Generating Revenue | |||
| 8. Accelerator/Incubator | 01-Nov-2020 | Completed | Generating Revenue | |||
| 7. Seed Round | 01-Feb-2020 | Completed | Generating Revenue | |||
| 6. Grant | 08-Oct-2019 | Completed | Generating Revenue | |||
| 5. Seed Round | 23-Oct-2018 | Completed | Generating Revenue | |||
| 4. Accelerator/Incubator | 01-Jan-2018 | Completed | Generating Revenue | |||
| 3. Accelerator/Incubator | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
RetiSpec Patents
RetiSpec Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260090709-A1 | Evaluating spectropolarimetric data packages of an eye for markers of disease | Pending | 23-Nov-2022 | ||
| WO-2024115962-A2 | Evaluating spectropolarimetric data packages of an eye for markers of disease | Inactive | 23-Nov-2022 | ||
| WO-2024115962-A3 | Evaluating spectropolarimetric data packages of an eye for markers of disease | Inactive | 23-Nov-2022 | ||
| WO-2024115962-A9 | Evaluating spectropolarimetric data packages of an eye for markers of disease | Inactive | 23-Nov-2022 | ||
| EP-4599220-A1 | Systems and methods for calibrating spectral devices | Pending | 07-Oct-2022 | A61B3/0016 |
RetiSpec Signals
RetiSpec Investors (22)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| C100 (Commercial Services) | Accelerator/Incubator | Minority | ||
| CRP Group (Clinics/Outpatient Services) | Corporation | Minority | ||
| Gentex | Corporation | Minority | ||
| Lilly USA | Corporation | Minority | ||
| Micasa Investments | Venture Capital | Minority |
RetiSpec FAQs
-
When was RetiSpec founded?
RetiSpec was founded in 2016.
-
Where is RetiSpec headquartered?
RetiSpec is headquartered in Toronto, Canada.
-
What is the size of RetiSpec?
RetiSpec has 31 total employees.
-
What industry is RetiSpec in?
RetiSpec’s primary industry is Decision/Risk Analysis.
-
Is RetiSpec a private or public company?
RetiSpec is a Private company.
-
What is RetiSpec’s current revenue?
The current revenue for RetiSpec is .
-
How much funding has RetiSpec raised over time?
RetiSpec has raised $18.2M.
-
Who are RetiSpec’s investors?
C100 (Commercial Services), CRP Group (Clinics/Outpatient Services), Gentex, Lilly USA, and Micasa Investments are 5 of 22 investors who have invested in RetiSpec.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process